tumor

by Michael E. Newman, Johns Hopkins University School of Medicine edited by Stephanie Baum, reviewed by Robert Egan  Editors’ notes An example of an OSET (Ossifying Spindled and Epithelioid Tumor), a newly discovered and classified benign soft tissue tumor. Here, the OSET is seen as a surgically excised gross specimen (upper left) and in the specimen radiograph (lower […]

by Medical University of Vienna edited by Gaby Clark, reviewed by Robert Egan  Editors’ notes LiPyDau treatment inhibits the growth of a patient-derived lung adenocarcinoma xenograft. Credit: Molecular Cancer (2025). DOI: 10.1186/s12943-025-02444-1 A research team has developed a new chemotherapeutic agent, LiPyDau, which shows remarkable efficacy against multiple tumor types in preclinical studies. Published in the journal Molecular Cancer, the study introduces a

by Li Yali, Chinese Academy of Sciences edited by Sadie Harley, reviewed by Robert Egan  Editors’ notes Overview of the method for large-scale production of iNK and CAR-iNK cells from cord blood CD34+ hematopoietic stem and progenitor cells. Credit: Prof. Wang’s Lab Chinese researchers have developed a novel method to efficiently engineer natural killer (NK) cells for cancer immunotherapy.

by Justin Jackson, Phys.org edited by Sadie Harley, reviewed by Robert Egan   Credit: Pixabay/CC0 Public Domain Satri-cel, a CLDN18.2-targeted CAR T-cell therapy, nearly doubles progression-free survival in patients with previously treated gastric or gastro-esophageal junction cancer, according to a multicenter randomized trial led by Peking University Cancer Hospital in China. Gastric and gastro-esophageal junction cancers remain among